Anti-cancer compounds
This invention provides, among other things, compounds useful for treating diseases such as cancer, pharmaceutical formulations containing such compounds, as well as combinations of these compounds with at least one additional therapeutic agent.
1. A compound, or a salt or a hydrate or a solvate thereof, having a structure according to formula (I):
wherein Z is —O— or —CH 2 — or —NH— or —N(CH 2 R 5 )— wherein R 5 is hydrogen or substituted or unsubstituted C 1 or C 2 or C 3 or C 4 or C 5 or C 6 or C 7 or C 8 or C 9 or C 10 alkyl; R 1 is hydrogen or substituted or unsubstituted C 1 or C 2 or C 3 or C 4 or C 5 or C 6 or C 7 or C 8 or C 9 or C 10 alkyl or substituted or unsubstituted C 1 or C 2 or C 3 or C 4 or C 5 or C 6 or C 7 or C 8 or C 9 or C 10 heteroalkyl or substituted or unsubstituted C 3 or C 4 or C 5 or C 6 cycloalkyl or unsubstituted phenyl or substituted or unsubstituted piperidinyl or substituted or unsubstituted azetidinyl; R 2 is hydrogen or methyl or ethyl or propyl or isopropyl or halogen; R 3 is chloro; R 4 is chloro.
2. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein R 2 is H.
3. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein Z is O.
4. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein R 1 is methyl.
5. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein R 1 is ethyl.
6. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein R 1 is C 1 or C 2 or C 3 or C 4 or C 5 or C 6 or C 7 or C 8 or C 9 or C 10 alkyl, substituted with unsubstituted C 1 or C 2 or C 3 or C 4 or C 5 or C 6 alkoxy.
7. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein R′ is C 2 alkyl, substituted with methoxy.
8. A pharmaceutical formulation comprising:
a) the compound, or a salt or a hydrate or a solvate thereof, of claim 1 ; and
b) a pharmaceutically acceptable excipient.
9. The pharmaceutical formulation of claim 8 , wherein the pharmaceutical formulation is a unit dosage form.
10. The pharmaceutical formulation of claim 8 , wherein the salt of the compound of is a pharmaceutically acceptable salt.
11. A method of inhibiting PARP1 and/or ABL1 and/or ABL2 and/or tubulin, comprising: contacting said PARP1 and/or ABL1 and/or ABL2 and/or tubulin with an effective amount of the compound of claim 1 , thereby inhibiting said PARP1 and/or ABL1 and/or ABL2 and/or tubulin.
12. A method of treating a disease in an animal, comprising: administering to an animal suffering from said disease a therapeutically effective amount of the compound of claim 1 , thereby treating the disease, and wherein the disease is multiple myeloma, lung cancer, ovarian cancer, pancreatic cancer, breast cancer, or mesothelioma.
13. The method of claim 12 , wherein the disease is multiple myeloma.
14. The method of claim 12 , wherein the animal is a human.
15. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, having a structure according to formula (XIII):
16. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, having a structure according to formula (XIV):
17. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein R 2 is methyl or halogen.
18. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein Z is O; R 2 is H or Cl or Br or CH 3 .